Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension (EnligHTN-IV)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
St. Jude Medical
ClinicalTrials.gov Identifier:
NCT01903187
First received: July 9, 2013
Last updated: September 19, 2016
Last verified: September 2016

July 9, 2013
September 19, 2016
October 2013
June 2014   (final data collection date for primary outcome measure)
  • The Primary Safety Endpoint Will be the Proportion of Subjects Who Experience Any Major Adverse Event (MAE) as Adjudicated by the Clinical Event Committee (CEC). [ Time Frame: 6 months post randomization ] [ Designated as safety issue: Yes ]
    The study enrollment was terminated early by the sponsor. This was not related to any safety issue. At the time enrollment was halted, only 2 treatment group randomizations had occurred.
  • The Primary Effectiveness Endpoint is the Reduction of Office Systolic Blood Pressure (OSBP) at Six (6) Months Post Randomization Compared to Baseline Between Groups [ Time Frame: 6 months post randomization ] [ Designated as safety issue: No ]
  • The Primary Safety Endpoint Will be the Proportion of Subjects Who Experience Any Major Adverse Event (MAE) as Adjudicated by the Clinical Event Committee (CEC). [ Time Frame: 6 months post randomization ] [ Designated as safety issue: Yes ]
  • The Primary Effectiveness Endpoint is the Reduction of Office Systolic Blood Pressure (OSBP) at Six (6) Months Post Randomization Compared to Baseline Between Groups [ Time Frame: 6 months post randomization ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01903187 on ClinicalTrials.gov Archive Site
  • Device or Procedure Related Adverse Events by Severity Post Randomization Through Six (6) Months [ Time Frame: 6 months post randomization ] [ Designated as safety issue: Yes ]
    The study enrollment was terminated early by the sponsor. This was not related to any safety issue. At the time enrollment was halted, only 2 treatment group randomizations had occurred, and sham group subjects were exited after their 1 month follow up visit. This was not enough to conduct the analysis.
  • The Number of Subjects That Experience Each Type of MAE [ Time Frame: 6 months post randomization ] [ Designated as safety issue: Yes ]
    The study enrollment was terminated early by the sponsor. This was not related to any safety issue. At the time enrollment was halted, only 2 treatment group randomizations had occurred, and sham group subjects were exited after their 1 month follow up visit. This was not enough to conduct the analysis.
  • Incidence of Achieving ≥ 10 mmHg, ≥ 15 mmHg, and ≥20 mmHg Reductions in OSBP [ Time Frame: 6 months post randomization, and all follow-up timepoints ] [ Designated as safety issue: No ]
    The study enrollment was terminated early by the sponsor. This was not related to any safety issue. At the time enrollment was halted, only 2 treatment group randomizations had occurred, and sham group subjects were exited after their 1 month follow up visit. This was not enough to conduct the analysis.
  • Reduction in Ambulatory Blood Pressure (ABP) Parameters [ Time Frame: baseline, 6 months post randomization, and all follow-up timepoints ] [ Designated as safety issue: No ]
    The study enrollment was terminated early by the sponsor. This was not related to any safety issue. At the time enrollment was halted, only 2 treatment group randomizations had occurred, and sham group subjects were exited after their 1 month follow up visit. This was not enough to conduct the analysis.
  • Device or Procedure Related Adverse Events by Severity Post Randomization Through Six (6) Months [ Time Frame: 6 months post randomization ] [ Designated as safety issue: Yes ]
  • The Number of Subjects That Experience Each Type of MAE [ Time Frame: 6 months post randomization ] [ Designated as safety issue: Yes ]
  • Incidence of Achieving ≥ 10 mmHg, ≥ 15 mmHg, and ≥20 mmHg Reductions in OSBP [ Time Frame: 6 months post randomization, and all follow-up timepoints ] [ Designated as safety issue: No ]
  • Reduction in Ambulatory Blood Pressure (ABP) Parameters [ Time Frame: baseline, 6 months post randomization, and all follow-up timepoints ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension
Multi-center, Randomized, Single-blind, Sham Controlled Clinical Investigation of Renal Denervation for Uncontrolled Hypertension
The purpose of the EnligHTN IV clinical investigation is to demonstrate the safety and effectiveness of the EnligHTN™ Renal Denervation System in the treatment of subjects with drug-resistant uncontrolled hypertension.

The study enrollment was terminated early by the sponsor. This was not related to any safety issue. At the time enrollment was halted, only 2 treatment group randomizations had occurred, and sham group subjects were exited after their 1 month follow up visit.

Subject randomized to the treatment group will be followed up for three years post procedure.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Hypertension
  • Device: EnligHTN Renal Denervation
    Renal artery angiogram plus bilateral renal denervation with the EnligHTN renal denervation system
  • Procedure: Sham
    Renal artery angiogram
  • Experimental: Renal Denervation
    Renal artery ablation with the EnligHTN™ Renal Denervation System.
    Intervention: Device: EnligHTN Renal Denervation
  • Active Comparator: Sham procedure
    Sham procedure
    Intervention: Procedure: Sham
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
4
November 2016
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject is ≥18 years of age and ≤ 80 years of age at time of informed consent for participation in the clinical investigation
  • Subject must be able and willing to provide written informed consent
  • Subject must be able and willing to comply with the required follow-up schedule
  • Subject has an office Systolic Blood Pressure ≥ 160 mmHg based on an average of 3 Blood Pressure readings at the confirmatory visit (except for subjects with Diabetes Mellitus Type II who must demonstrate an office Systolic Blood Pressure of ≥ 150 mmHg)
  • Subject has a daytime mean Systolic 24-hour Ambulatory Blood Pressure value of ≥ 140 mmHg as measured during the two week screening period and confirmed at the confirmatory visit
  • Subject is taking ≥ 3 antihypertensive medications concurrently at full tolerated doses (this must include one diuretic) or subject is taking a diuretic and has a documented intolerance to at least two (2) out of the three (3) remaining major classes of anti-hypertensives (ACE / ARB, Calcium Channel Blockers, Beta blockers and is unable to take 3 anti-hypertensive drugs)

    o Intolerance is defined as an absolute contraindication to an anti-hypertensive medication according to the approved labeling or an inability to take an anti-hypertensive medication as prescribed due to an adverse drug effect including an immune mediated response or interaction with other medications.

  • Subjects must be on a stable antihypertensive medication regimen for a minimum of 2 weeks prior to completing the initial screening visit and the medication regimen must remain unchanged during the 2 week screening period following signing consent. Subject must be assessed at the confirmatory visit with no expected changes for at least six (6) months

Exclusion Criteria:

  • Subject has had a previous renal denervation attempt
  • Subject has known cause of secondary hypertension other than sleep apnea
  • Subjects with significant renovascular abnormalities such as renal artery stenosis >30%, previous renal stenting or angioplasty, renal artery occlusion, renal vein thrombosis, renal aneurysm or renal atheroembolism
  • Subject has had a myocardial infarction, unstable angina pectoris, or cerebrovascular accident < 180 days prior to enrollment
  • Subject has hemodynamically significant valvular heart disease as determined by a Study Investigator
  • Subject is expected to have any cardiovascular intervention within 180 days of enrollment
  • Subject has blood clotting abnormalities such as thrombocytopenia, hemophilia, or significant anemia
  • Subject life expectancy is < 12 months, as determined by a Study Investigator
  • Subject is participating in another Clinical Investigation (IND or IDE)
  • Subject is pregnant, nursing, or of childbearing potential and is not using adequate contraceptive methods
  • Subject has active systemic infection as determined by a Study Investigator
  • Subject has main renal arteries with diameter(s) < 4 mm in diameter or < 20 mm in length or multiple renal arteries where the main renal arteries supply <75% of the kidney
  • Subject has eGFR < 45 mL/min per 1.73 m2 using the MDRD formula
  • Subject has evidence of significant AAA defined as an aneurysm size of ≥5.0 cm in width and/or involving the renal arteries, and/or requiring surgical or percutaneous intervention within 6 months of enrollment.
  • Subject has had >1 in-patient hospitalization for a hypertensive crisis within 12 months
  • Subject has a condition which would interfere with the accurate interpretation of the study endpoints
  • Any condition that would prohibit or interfere with the ability to obtain accurate Blood Pressure measurements using the CIP specific automatic Blood Pressure monitor
  • Subject has Systolic Blood Pressure values which are greater than 20mmHg apart after six (6) measurements as assessed at the confirmatory visit
Both
18 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01903187
1204
Yes
Not Provided
Not Provided
St. Jude Medical
St. Jude Medical
Not Provided
Study Chair: William B White, MD University of Connecticut Health Center
Study Chair: William A Gray, MD Columbia University
St. Jude Medical
September 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP